Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma

Abstract

Abstract. We introduced concurrent neoadjuvant chemoradiotherapy (CCRT) with S-1, an oral fluoropyrimidine, as treatment for oral squamous cell carcinoma (OSCC) from October 2005. The clinical usefulness and medical safety of CCRT with S-1 (S-1 group) for OSCC were analyzed and compared with CCRT using super-selective intra-arterial infusion (AI group). The subjects in the S-1 group underwent external irradiation, at a total dose of 30 Gy, with S-1 chemotherapy. The AI group received cisplatin (CDDP) or carboplatin (CBDCA) combined with daily radiotherapy at a total dose of 40 Gy. The histological effects and disease-specific survival rates were almost equivalent in the S-1 and AI groups. Adverse events were less frequent in the S-1 group, while hematological toxicity, including anemia, thrombopenia and pharyngeal edema, was observed in the AI group. The results of this study indicate that CCRT combined with S-1 is a more effective and safer treatment for OSCC than AI.

Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma

“…Miyawaki et al demonstrated that the administration of S-1 chemoradiotherapy at 30 Gy to treat OSCC at stages II-IV, which was similar to the present regimen, was histopathologically effective in 73.7% of patients (30). The DSS rate of the previous study was 88.8%, which is similar to the present results (30). These results indicate that increasing the total radiation dose may not affect the patient outcome, but it yields an effective primary tumor response.…”

“…However, the OS rate of the patients with stage III/IV OSCC in the present study was 84.0%, which yielded a similar survival curve to those obtained in previous studies (6)(7)(8)(9)23,24). Miyawaki et al demonstrated that the administration of S-1 chemoradiotherapy at 30 Gy to treat OSCC at stages II-IV, which was similar to the present regimen, was histopathologically effective in 73.7% of patients (30). The DSS rate of the previous study was 88.8%, which is similar to the present results (30).…”

Effect of TTLL12 on tubulin tyrosine nitration as a novel target for screening anticancer drugs<em> in&nbsp;vitro</em>

“…It is well-known that carboplatin (CDDP), 5-fluorouracil (5-FU), cyclophosphamide (CTX) and methotrexate (MTX) exert notable effects on cancer development but have no effects on microtubules ( 32 – 35 ). Stable TTLL12-overexpressing SCC-25 cells were seeded into 96-well plates at a density of 10,000 cells/well and incubated in modified Eagle's medium supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 40 µg/ml gentamycin.…”

Intraoperative frozen section histological analysis of resection samples is useful for the control of primary lesions in patients with oral squamous cell carcinoma

“…The preservation of the morphological characteristics of the oral cavity and functions such as mastication, swallowing, speech and esthetics is crucial in the treatment of advanced OSCC (11). Several studies have reported the effect of preoperative chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity (11)(12)(13)(14). As a result, surgery was performed as the main treatment and chemoradiotherapy was performed as preoperative treatment throughout this period.…”